Europe Early Toxicity Testing Market

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2       EUROPE EARLY TOXICITY TESTING MARKET BY TECHNIQUE

           2.1      OVERVIEW

           2.2      IN VIVO

                         2.2.1      IN VIVO MARKET, BY COUNTRY

           2.3      IN VITRO

                         2.3.1      IN VITRO MARKET, BY TECHNIQUE

                                          2.3.1.1      CELL CULTURE MARKET, BY COUNTRY

                                          2.3.1.2      PCR MARKET, BY COUNTRY

                                          2.3.1.3      ELISA MARKET, BY COUNTRY

                                          2.3.1.4      WESTERN BLOTTING MARKET, BY COUNTRY

                                          2.3.1.5      PROTEIN BINDING ASSAYS MARKET, BY COUNTRY

                         2.3.2      IN VITRO MARKET, BY COUNTRY

           2.4      IN SILICO

                         2.4.1      IN SILICO MARKET, BY COUNTRY

3       EUROPE EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT

           3.1      OVERVIEW

           3.2      GENOTOXICITY

                         3.2.1      GENOTOXICITY MARKET, BY COUNTRY

           3.3      DERMAL TOXICITY

                         3.3.1      DERMAL TOXICITY MARKET, BY COUNTRY

           3.4      SKIN TOXICITY

                         3.4.1      SKIN TOXICITY MARKET, BY COUNTRY

           3.5      OCULAR TOXICITY

                         3.5.1      OCULAR TOXICITY MARKET, BY COUNTRY

           3.6      PHOTOTOXICITY

                         3.6.1      PHOTOTOXICITY MARKET, BY COUNTRY

           3.7      OTHERS

                         3.7.1      OTHERS MARKET, BY COUNTRY

4       EUROPE EARLY TOXICITY TESTING MARKET BY END USER

           4.1      OVERVIEW

           4.2      PHARMACEUTICAL INDUSTRY

                         4.2.1      PHARMACEUTICAL INDUSTRY MARKET, BY COUNTRY

           4.3      COSMETIC INDUSTRY

                         4.3.1      COSMETIC INDUSTRY MARKET, BY COUNTRY

           4.4      CHEMICAL INDUSTRY

                         4.4.1      CHEMICAL INDUSTRY MARKET, BY COUNTRY

           4.5      FOOD INDUSTRY

                         4.5.1      FOOD INDUSTRY MARKET, BY COUNTRY

           4.6      OTHERS

                         4.6.1      OTHERS MARKET, BY COUNTRY

5      EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY

           5.1     OVERVIEW

           5.2     GERMANY

                         5.2.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.2.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.2.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.3     FRANCE

                         5.3.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.3.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.3.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.4     ITALY

                         5.4.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.4.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.4.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.5     SPAIN

                         5.5.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.5.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.5.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.6     UNITED KINGDOM

                         5.6.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.6.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.6.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.7     RUSSIA

                         5.7.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.7.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.7.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.8     SWEDEN

                         5.8.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.8.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.8.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.9     NORWAY

                         5.9.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.9.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.9.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.10     DENMARK

                         5.10.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.10.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.10.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.11     NETHERLANDS

                         5.11.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.11.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.11.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.12     FINLAND

                         5.12.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.12.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.12.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.13     REST OF EUROPE

                         5.13.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.13.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.13.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

6      COMPANY PROFILES

           6.1   INOTIV INC.

                         6.1.1   COMPANY OVERVIEW

                         6.1.2   COMPANY SNAPSHOT

                         6.1.3   OPERATING BUSINESS SEGMENTS

                         6.1.4   PRODUCT PORTFOLIO

                         6.1.5   BUSINESS PERFORMANCE

                         6.1.6   BUSINESS SEGMENTS

                         6.1.7   GEOGRAPHIC SEGMENTS

                         6.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.1.9   PRIMARY MARKET COMPETITORS

           6.2   BIO-RAD LABORATORIES INC.

                         6.2.1   COMPANY OVERVIEW

                         6.2.2   COMPANY SNAPSHOT

                         6.2.3   OPERATING BUSINESS SEGMENTS

                         6.2.4   PRODUCT PORTFOLIO

                         6.2.5   BUSINESS PERFORMANCE

                         6.2.6   BUSINESS SEGMENTS

                         6.2.7   GEOGRAPHIC SEGMENTS

                         6.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.2.9   PRIMARY MARKET COMPETITORS

           6.3   EVOTEC A.G.

                         6.3.1   COMPANY OVERVIEW

                         6.3.2   COMPANY SNAPSHOT

                         6.3.3   OPERATING BUSINESS SEGMENTS

                         6.3.4   PRODUCT PORTFOLIO

                         6.3.5   BUSINESS PERFORMANCE

                         6.3.6   BUSINESS SEGMENTS

                         6.3.7   GEOGRAPHIC SEGMENTS

                         6.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.3.9   PRIMARY MARKET COMPETITORS

           6.4   AGILENT TECHNOLOGIES INC.

                         6.4.1   COMPANY OVERVIEW

                         6.4.2   COMPANY SNAPSHOT

                         6.4.3   OPERATING BUSINESS SEGMENTS

                         6.4.4   PRODUCT PORTFOLIO

                         6.4.5   BUSINESS PERFORMANCE

                         6.4.6   BUSINESS SEGMENTS

                         6.4.7   GEOGRAPHIC SEGMENTS

                         6.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.4.9   PRIMARY MARKET COMPETITORS

           6.5   WUXI APPTEC

                         6.5.1   COMPANY OVERVIEW

                         6.5.2   COMPANY SNAPSHOT

                         6.5.3   OPERATING BUSINESS SEGMENTS

                         6.5.4   PRODUCT PORTFOLIO

                         6.5.5   BUSINESS PERFORMANCE

                         6.5.6   BUSINESS SEGMENTS

                         6.5.7   GEOGRAPHIC SEGMENTS

                         6.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.5.9   PRIMARY MARKET COMPETITORS

           6.6   BRUKER

                         6.6.1   COMPANY OVERVIEW

                         6.6.2   COMPANY SNAPSHOT

                         6.6.3   OPERATING BUSINESS SEGMENTS

                         6.6.4   PRODUCT PORTFOLIO

                         6.6.5   BUSINESS PERFORMANCE

                         6.6.6   BUSINESS SEGMENTS

                         6.6.7   GEOGRAPHIC SEGMENTS

                         6.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.6.9   PRIMARY MARKET COMPETITORS

           6.7   PERKINELMER INC.

                         6.7.1   COMPANY OVERVIEW

                         6.7.2   COMPANY SNAPSHOT

                         6.7.3   OPERATING BUSINESS SEGMENTS

                         6.7.4   PRODUCT PORTFOLIO

                         6.7.5   BUSINESS PERFORMANCE

                         6.7.6   BUSINESS SEGMENTS

                         6.7.7   GEOGRAPHIC SEGMENTS

                         6.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.7.9   PRIMARY MARKET COMPETITORS

           6.8   ENZO BIOCHEM INC.

                         6.8.1   COMPANY OVERVIEW

                         6.8.2   COMPANY SNAPSHOT

                         6.8.3   OPERATING BUSINESS SEGMENTS

                         6.8.4   PRODUCT PORTFOLIO

                         6.8.5   BUSINESS PERFORMANCE

                         6.8.6   BUSINESS SEGMENTS

                         6.8.7   GEOGRAPHIC SEGMENTS

                         6.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.8.9   PRIMARY MARKET COMPETITORS

           6.9   DANAHER CORPORATION

                         6.9.1   COMPANY OVERVIEW

                         6.9.2   COMPANY SNAPSHOT

                         6.9.3   OPERATING BUSINESS SEGMENTS

                         6.9.4   PRODUCT PORTFOLIO

                         6.9.5   BUSINESS PERFORMANCE

                         6.9.6   BUSINESS SEGMENTS

                         6.9.7   GEOGRAPHIC SEGMENTS

                         6.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.9.9   PRIMARY MARKET COMPETITORS

           6.10   EUROFINS SCIENTIFIC SE

                         6.10.1   COMPANY OVERVIEW

                         6.10.2   COMPANY SNAPSHOT

                         6.10.3   OPERATING BUSINESS SEGMENTS

                         6.10.4   PRODUCT PORTFOLIO

                         6.10.5   BUSINESS PERFORMANCE

                         6.10.6   BUSINESS SEGMENTS

                         6.10.7   GEOGRAPHIC SEGMENTS

                         6.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.10.9   PRIMARY MARKET COMPETITORS

           6.11   CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

                         6.11.1   COMPANY OVERVIEW

                         6.11.2   COMPANY SNAPSHOT

                         6.11.3   OPERATING BUSINESS SEGMENTS

                         6.11.4   PRODUCT PORTFOLIO

                         6.11.5   BUSINESS PERFORMANCE

                         6.11.6   BUSINESS SEGMENTS

                         6.11.7   GEOGRAPHIC SEGMENTS

                         6.11.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.11.9   PRIMARY MARKET COMPETITORS

           6.12   LABCORP DRUG DEVELOPMENT.

                         6.12.1   COMPANY OVERVIEW

                         6.12.2   COMPANY SNAPSHOT

                         6.12.3   OPERATING BUSINESS SEGMENTS

                         6.12.4   PRODUCT PORTFOLIO

                         6.12.5   BUSINESS PERFORMANCE

                         6.12.6   BUSINESS SEGMENTS

                         6.12.7   GEOGRAPHIC SEGMENTS

                         6.12.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.12.9   PRIMARY MARKET COMPETITORS

           6.13   PROMEGA CORPORATION

                         6.13.1   COMPANY OVERVIEW

                         6.13.2   COMPANY SNAPSHOT

                         6.13.3   OPERATING BUSINESS SEGMENTS

                         6.13.4   PRODUCT PORTFOLIO

                         6.13.5   BUSINESS PERFORMANCE

                         6.13.6   BUSINESS SEGMENTS

                         6.13.7   GEOGRAPHIC SEGMENTS

                         6.13.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.13.9   PRIMARY MARKET COMPETITORS

           6.14   INSPHERO AG

                         6.14.1   COMPANY OVERVIEW

                         6.14.2   COMPANY SNAPSHOT

                         6.14.3   OPERATING BUSINESS SEGMENTS

                         6.14.4   PRODUCT PORTFOLIO

                         6.14.5   BUSINESS PERFORMANCE

                         6.14.6   BUSINESS SEGMENTS

                         6.14.7   GEOGRAPHIC SEGMENTS

                         6.14.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.14.9   PRIMARY MARKET COMPETITORS

           6.15   THERMO FISHER SCIENTIFIC INC.

                         6.15.1   COMPANY OVERVIEW

                         6.15.2   COMPANY SNAPSHOT

                         6.15.3   OPERATING BUSINESS SEGMENTS

                         6.15.4   PRODUCT PORTFOLIO

                         6.15.5   BUSINESS PERFORMANCE

                         6.15.6   BUSINESS SEGMENTS

                         6.15.7   GEOGRAPHIC SEGMENTS

                         6.15.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.15.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 2. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 3. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 4. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 5. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 7. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 8. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 9. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 10. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 11. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 12. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 13. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 14. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 15. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 16. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 17. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 18. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 19. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 20. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 21. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 22. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 23. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 24. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 25. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 26. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 27. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 28. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 29. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 30. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 31. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 32. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 33. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 34. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 35. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 36. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 37. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 38. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 39. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 40. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 41. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 42. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 43. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 44. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 45. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 46. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 47. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 48. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 49. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 50. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 51. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 52. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 53. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 54. INOTIV INC.: COMPANY SNAPSHOT

TABLE 55. INOTIV INC: OPERATING SEGMENTS

TABLE 56. INOTIV INC.: PR0DUCT PORTFOLIO

TABLE 57. INOTIV INC.: BUSINESS SEGMENT

TABLE 58. INOTIV INC.: GEOGRAPHIC SEGMENT

TABLE 59. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 60. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 61. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 62. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 63. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT

TABLE 64. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT

TABLE 65. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 66. EVOTEC A.G.: COMPANY SNAPSHOT

TABLE 67. EVOTEC A.G.: OPERATING SEGMENTS

TABLE 68. EVOTEC A.G.: PRODUCT PORTFOLIO

TABLE 69. EVOTEC A.G.: BUSINESS SEGMENT

TABLE 70. EVOTEC A.G.: GEOGRAPHIC SEGMENT

TABLE 71. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 72. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 73. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 74. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 75. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT

TABLE 76. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT

TABLE 77. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 78. WUXI APPTEC.: COMPANY SNAPSHOT

TABLE 79. WUXI APPTEC: OPERATING SEGMENTS

TABLE 80. WUXI APPTEC.: PR0DUCT PORTFOLIO

TABLE 81. WUXI APPTEC.: BUSINESS SEGMENT

TABLE 82. WUXI APPTEC.: GEOGRAPHIC SEGMENT

TABLE 83. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 84. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 85. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 86. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 87. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 88. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 89. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 90. BRUKER: COMPANY SNAPSHOT

TABLE 91. BRUKER: OPERATING SEGMENTS

TABLE 92. BRUKER: PRODUCT PORTFOLIO

TABLE 93. BRUKER: BUSINESS SEGMENT

TABLE 94. BRUKER: GEOGRAPHIC SEGMENT

TABLE 95. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 96. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 97. PERKINELMER INC.: OPERATING SEGMENTS

TABLE 98. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 99. PERKINELMER INC.: BUSINESS SEGMENT

TABLE 100. PERKINELMER INC.: GEOGRAPHIC SEGMENT

TABLE 101. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 102. ENZO BIOCHEM INC.: COMPANY SNAPSHOT

TABLE 103. ENZO BIOCHEM INC.: OPERATING SEGMENTS

TABLE 104. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO

TABLE 105. ENZO BIOCHEM INC.: BUSINESS SEGMENT

TABLE 106. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT

TABLE 107. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 108. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 109. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 110. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 111. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 112. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 113. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT

TABLE 114. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO

TABLE 115. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT

TABLE 116. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 117. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT

TABLE 118. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS

TABLE 119. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO

TABLE 120. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT

TABLE 121. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT

TABLE 122. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 123. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT

TABLE 124. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS

TABLE 125. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO

TABLE 126. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT

TABLE 127. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT

TABLE 128. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 129. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 130. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 131. INSPHERO AG: COMPANY SNAPSHOT

TABLE 132. INSPHERO AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 2. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 3. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 4. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 5. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 7. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 8. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 9. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 10. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 11. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 12. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 13. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 14. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 15. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 16. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 17. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 18. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 19. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 20. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 21. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 22. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 23. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 24. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 25. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 26. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 27. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 28. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 29. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 30. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 31. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 32. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 33. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 34. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 35. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 36. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 37. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 38. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 39. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 40. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 41. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 42. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 43. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 44. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 45. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 46. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 47. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 48. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 49. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 50. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 51. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 52. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 53. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 54. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 55. INOTIV INC: PRIMARY MARKET COMPETITORS

FIGURE 56. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 57. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS

FIGURE 58. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)

FIGURE 59. EVOTEC A.G.: PRIMARY MARKET COMPETITORS

FIGURE 60. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)

FIGURE 61. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS

FIGURE 62. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 63. WUXI APPTEC: PRIMARY MARKET COMPETITORS

FIGURE 64. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 65. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 66. BRUKER: NET SALES, 2019–2021 ($MILLION)

FIGURE 67. BRUKER: PRIMARY MARKET COMPETITORS

FIGURE 68. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 69. PERKINELMER INC.: PRIMARY MARKET COMPETITORS

FIGURE 70. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 71. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS

FIGURE 72. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 73. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 74. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 75. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS

FIGURE 76. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 77. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS

FIGURE 78. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 79. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS

FIGURE 80. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 81. INSPHERO AG: PRIMARY MARKET COMPETITORS

 

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

 

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

              

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.